A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials
Immunooncology; Predictive biomarkers; Tumor microenvironment
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:11351/10525 |
| Acceso en línea: | https://hdl.handle.net/11351/10525 |
| Access Level: | acceso abierto |
| Palabra clave: | Càncer - Immunoteràpia Càncer - Aspectes genètics Fisiologia cel·lular DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/genetics ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/genética TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral |
| id |
ES_6fefcea059ac12f72192e2ddfc8d79c0 |
|---|---|
| oai_identifier_str |
oai:recercat.cat:11351/10525 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| title |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| spellingShingle |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials Bareche, Yacine Càncer - Immunoteràpia Càncer - Aspectes genètics Fisiologia cel·lular DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/genetics ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/genética TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral |
| title_short |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| title_full |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| title_fullStr |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| title_full_unstemmed |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| title_sort |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials |
| dc.creator.none.fl_str_mv |
Bareche, Yacine Abbas-Aghababazadeh, Farnoosh Lo Giacco, Deborah Martin Casado, Agatha Saavedra Gadea, Omar Berche, Roger Mirallas, Oriol Jimenez, Jose Valverde Morales, Claudia Maria Díez García, Marc Hernando-Calvo, Alberto Vila-Casadesús, Maria Gonzalez Medina, Alberto Brana, Irene Vieito , Maria fasani, roberta Mancuso, Francesco Mattia Saoudi Gonzalez, Nadia Elez, Elena Capdevila Castillon, Jaume OAKNIN, ANA Saura Manich, Cristina Nuciforo, Paolo Seoane, Joan Tabernero, Josep GARRALDA, Elena Vivancos, Ana MUÑOZ COUSELO, EVA Dienstmann, Rodrigo Carles, Joan Suárez, Cristina Macarulla, Teresa FELIP, ENRIQUETA |
| author |
Bareche, Yacine |
| author_facet |
Bareche, Yacine Abbas-Aghababazadeh, Farnoosh Lo Giacco, Deborah Martin Casado, Agatha Saavedra Gadea, Omar Berche, Roger Mirallas, Oriol Jimenez, Jose Valverde Morales, Claudia Maria Díez García, Marc Hernando-Calvo, Alberto Vila-Casadesús, Maria Gonzalez Medina, Alberto Brana, Irene Vieito , Maria fasani, roberta Mancuso, Francesco Mattia Saoudi Gonzalez, Nadia Elez, Elena Capdevila Castillon, Jaume OAKNIN, ANA Saura Manich, Cristina Nuciforo, Paolo Seoane, Joan Tabernero, Josep GARRALDA, Elena Vivancos, Ana MUÑOZ COUSELO, EVA Dienstmann, Rodrigo Carles, Joan Suárez, Cristina Macarulla, Teresa FELIP, ENRIQUETA |
| author_role |
author |
| author2 |
Abbas-Aghababazadeh, Farnoosh Lo Giacco, Deborah Martin Casado, Agatha Saavedra Gadea, Omar Berche, Roger Mirallas, Oriol Jimenez, Jose Valverde Morales, Claudia Maria Díez García, Marc Hernando-Calvo, Alberto Vila-Casadesús, Maria Gonzalez Medina, Alberto Brana, Irene Vieito , Maria fasani, roberta Mancuso, Francesco Mattia Saoudi Gonzalez, Nadia Elez, Elena Capdevila Castillon, Jaume OAKNIN, ANA Saura Manich, Cristina Nuciforo, Paolo Seoane, Joan Tabernero, Josep GARRALDA, Elena Vivancos, Ana MUÑOZ COUSELO, EVA Dienstmann, Rodrigo Carles, Joan Suárez, Cristina Macarulla, Teresa FELIP, ENRIQUETA |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Institut Català de la Salut [Hernando-Calvo A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vila-Casadesús M, Gonzalez-Medina A, Lo Giacco D, Martin A, Fasani R, Mancuso F, Berche R, Jimenez J, Dienstmann R, Nuciforo P, Seoane J, Vivancos A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bareche Y] Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada. [Abbas-Aghababazadeh F] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Saavedra O, Brana I, Vieito M, Mirallas O, Saoudi Gonzalez N, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Carles Galceran J, Felip E, Tabernero J, Garralda E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus |
| dc.subject.none.fl_str_mv |
Càncer - Immunoteràpia Càncer - Aspectes genètics Fisiologia cel·lular DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/genetics ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/genética TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral |
| topic |
Càncer - Immunoteràpia Càncer - Aspectes genètics Fisiologia cel·lular DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/genetics ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/genética TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral |
| description |
Immunooncology; Predictive biomarkers; Tumor microenvironment |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2023 2023 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/11351/10525 |
| url |
https://hdl.handle.net/11351/10525 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Med;4(10) https://doi.org/10.1016/j.medj.2023.07.006 |
| dc.rights.none.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
Scientia reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869410543905800192 |
| spelling |
A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trialsBareche, YacineAbbas-Aghababazadeh, FarnooshLo Giacco, DeborahMartin Casado, AgathaSaavedra Gadea, OmarBerche, RogerMirallas, OriolJimenez, JoseValverde Morales, Claudia MariaDíez García, MarcHernando-Calvo, AlbertoVila-Casadesús, MariaGonzalez Medina, AlbertoBrana, IreneVieito , Mariafasani, robertaMancuso, Francesco MattiaSaoudi Gonzalez, NadiaElez, ElenaCapdevila Castillon, JaumeOAKNIN, ANASaura Manich, CristinaNuciforo, PaoloSeoane, JoanTabernero, JosepGARRALDA, ElenaVivancos, AnaMUÑOZ COUSELO, EVADienstmann, RodrigoCarles, JoanSuárez, CristinaMacarulla, TeresaFELIP, ENRIQUETACàncer - ImmunoteràpiaCàncer - Aspectes genèticsFisiologia cel·lularDISEASES::NeoplasmsOther subheadings::Other subheadings::Other subheadings::/geneticsANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::ImmunotherapyPHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor MicroenvironmentENFERMEDADES::neoplasiasOtros calificadores::Otros calificadores::Otros calificadores::/genéticaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapiaFENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoralImmunooncology; Predictive biomarkers; Tumor microenvironmentInmunooncología; Biomarcadores predictivos; Microambiente tumoralImmunooncologia; Biomarcadors predictius; Microambient tumoralBackground Immunotherapy is effective, but current biomarkers for patient selection have proven modest sensitivity. Here, we developed VIGex, an optimized gene signature based on the expression level of 12 genes involved in immune response with RNA sequencing. Methods We implemented VIGex using the nCounter platform (Nanostring) on a large clinical cohort encompassing 909 tumor samples across 45 tumor types. VIGex was developed as a continuous variable, with cutoffs selected to detect three main categories (hot, intermediate-cold and cold) based on the different inflammatory status of the tumor microenvironment. Findings Hot tumors had the highest VIGex scores and exhibited an increased abundance of tumor-infiltrating lymphocytes as compared with the intermediate-cold and cold. VIGex scores varied depending on tumor origin and anatomic site of metastases, with liver metastases showing an immunosuppressive tumor microenvironment. The predictive power of VIGex-Hot was observed in a cohort of 98 refractory solid tumor from patients treated in early-phase immunotherapy trials and its clinical performance was confirmed through an extensive metanalysis across 13 clinically annotated gene expression datasets from 877 patients treated with immunotherapy agents. Last, we generated a pan-cancer biomarker platform that integrates VIGex categories with the expression levels of immunotherapy targets under development in early-phase clinical trials. Conclusions Our results support the clinical utility of VIGex as a tool to aid clinicians for patient selection and personalized immunotherapy interventions.A.H.C. would like to acknowledge fellowship funding from the Spanish Society of Medical Oncology (SEOM), CRIS Contra el Cancer and Hold'em For Life Oncology Fellowship. This research has been funded by the Comprehensive Program of Cancer Immunotherapy & Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021) and the 2020–2021 Division of Medical Oncology and Hematology (DMOH) Fellowship award at Princess Margaret Cancer Centre. VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support of this research. Authors from VHIO acknowledge the State Agency for Research (Agencia Estatal de Investigación) for providing financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033). A.V. was the recipient of a project award from the FAECC (AVP/18/AECC/3219) and received funding from the Advanced Molecular Diagnostic (DIAMAV) program from the FERO Foundation. Graphical abstract was created with BioRender.com. Diagram in Figure 3B was created with SankeyMATIC (sankeymatic.com).ElsevierInstitut Català de la Salut[Hernando-Calvo A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Vila-Casadesús M, Gonzalez-Medina A, Lo Giacco D, Martin A, Fasani R, Mancuso F, Berche R, Jimenez J, Dienstmann R, Nuciforo P, Seoane J, Vivancos A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bareche Y] Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada. Faculty of Pharmacy, Université de Montréal, Montréal, QC, Canada. [Abbas-Aghababazadeh F] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Saavedra O, Brana I, Vieito M, Mirallas O, Saoudi Gonzalez N, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Carles Galceran J, Felip E, Tabernero J, Garralda E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SpainVall d'Hebron Barcelona Hospital Campus202320232023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/10525Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésMed;4(10)https://doi.org/10.1016/j.medj.2023.07.006Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/105252026-05-29T05:05:01Z |
| score |
15,811543 |